Jeroen Bakker

Phasecraft is the quantum algorithms company. We’re building the mathematical foundations for quantum computing applications that solve real-world problems. Our team brings together many of the world’s leading quantum scientists, including founders Toby Cubitt, Ashley Montanaro, and John Morton.

Sparrow Quantum is a spin-out from a powerhouse of innovation—Professor Peter Lodahl’s research group at the Niels Bohr Institute. With 25+ years of groundbreaking research and nearly a decade of engineering expertise, we are dedicated to advancing the frontier of high-quality photon generation for quantum technologies. We specialize in light-matter interfaces—the essential building blocks for scaling optical quantum technologies. At the core of our innovation is our on-chip deterministic single-photon source, a breakthrough technology that sets industry benchmarks and is trusted by quantum technology leaders worldwide. By delivering high-purity, high-efficiency photons, Sparrow Quantum empowers its partners and customers to push the boundaries of quantum computing and secure communication, transforming the immense potential of quantum technology into real-world innovation and impact. Learn more at www.sparrowquantum.com

Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body’s natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.

Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic. Read more at www.adcendo.com

ISD Immunotech is developing STING modulators to treat severe Systemic lupus erythematosus (SLE) or Lupus by targeting the STING pathway. SLE is a complex and devastating autoimmune disease with few to no good options for treatment especially for the most severe patients. STimulator of INterferon Gene (STING) is a target that controls innate immunity and has shown to be overactive in severe SLE making it an exciting new therapeutic target for SLE.

Antag Therapeutics is a biotechnology company pioneering personal and flexible obesity treatment through GIP receptor antagonism. Antag’s lead molecule AT-7687 is specifically designed to target and deactivate the GIP receptor, a genetically-validated pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction – and is mechanistically distinct from GLP-1 therapies. Antag’s GIPR antagonist approach stems from the work of the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, two co-founders of the business. Antag’s vision is that all people living with obesity, diabetes and overweight have a personal treatment option that goes beyond weight loss to improve long-term health, without having to compromise on tolerability.

BiOrigin provides different types of strategic and operational support to companies and projects in order to help them steer through the critical start-up and subsequent growth phase.

At Amsterdam UMC, more than 15,000 professionals strive to provide good and accessible care. For the generations of today and tomorrow. The two medical university centers in Amsterdam, AMC and VUmc, are working together towards a future in which we prevent illnesses and make the best treatment available to all patients. To this end, we develop new methods for diagnostics and treatment together with professionals from other renowned national and international institutions. We treat over 350,000 patients a year at both our sites - AMC and VUmc. Our main focus is on complex patient care and highly-specialized treatment of rare medical conditions. At Amsterdam UMC, we teach and train thousands of young people to become doctors, specialists or nurses. Our researchers are clustered in eight research centers so that we can achieve our ambition of executing international, cutting-edge research. At Amsterdam UMC, AMC and VUmc are working together on academic patient care, scientific research and teaching & training.

Phasecraft is the quantum algorithms company. We’re building the mathematical foundations for quantum computing applications that solve real-world problems. Our team brings together many of the world’s leading quantum scientists, including founders Toby Cubitt, Ashley Montanaro, and John Morton.

Sparrow Quantum is a spin-out from a powerhouse of innovation—Professor Peter Lodahl’s research group at the Niels Bohr Institute. With 25+ years of groundbreaking research and nearly a decade of engineering expertise, we are dedicated to advancing the frontier of high-quality photon generation for quantum technologies. We specialize in light-matter interfaces—the essential building blocks for scaling optical quantum technologies. At the core of our innovation is our on-chip deterministic single-photon source, a breakthrough technology that sets industry benchmarks and is trusted by quantum technology leaders worldwide. By delivering high-purity, high-efficiency photons, Sparrow Quantum empowers its partners and customers to push the boundaries of quantum computing and secure communication, transforming the immense potential of quantum technology into real-world innovation and impact. Learn more at www.sparrowquantum.com

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S and manages an investment portfolio, with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, Principal and Planetary Health Investments teams, Novo Holdings invests in life science companies at all stages of development.

Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body’s natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.

Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic. Read more at www.adcendo.com